Navigation Links
Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Date:11/15/2007

Safety Analysis Shows Good Tolerance with No Serious Adverse Reactions

BERKELEY HEIGHTS, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) released findings from the initial clinical dosing of G4544, the Company's proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. The Phase 1 study, which was conducted in normal volunteers, has shown good tolerance with oral bioavailability of the active ingredient, and an excellent safety profile without serious adverse reactions. The findings were released in an abstract published in the proceedings of the upcoming annual meeting of the American Society of Hematology.

G4544 is a new tablet formulation using delivery technology developed by Emisphere Technologies, Inc. that enables oral absorption of the active ingredient contained in Ganite(R) (gallium nitrate injection). Ganite(R) is marketed by Genta and approved in the U.S. for treatment of cancer-related hypercalcemia that is resistant to hydration. Low doses of the active ingredient in Ganite administered by intravenous or subcutaneous injections have shown clinical activity in a range of skeletal diseases, including hypercalcemia, bone metastasis (myeloma and breast cancer), Paget's disease, and osteoporosis.

The initial clinical trial was a Phase 1 study of escalating single doses of G4544 in 30 normal volunteers. The endpoints of the study were to determine safety and to assess pharmacokinetics and oral bioavailability. The drug was tested over a dosing range of the active ingredient from 30 to 150 mg, and no adverse effects attributable to G4544 were observed in this study. Initial analysis of plasma samples of low doses sh
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
11. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... LOS ANGELES , Sept. 1, 2015 /PRNewswire/ ... biopharmaceutical research and development company specializing in oncology, ... Chairman and Chief Executive Officer, and David ... Investor Relations, will present a corporate overview at ... spotlight the biotechnology and healthcare industries: the FBR ...
(Date:9/1/2015)... , Sept. 1, 2015 Pressure ... a leader in the development and sale of ... solutions to the worldwide life sciences industry, today ... that suggest the Company,s PCT Platform could play ... personalized/precision medicine.  This role is based on PCT,s ...
(Date:9/1/2015)... -- BerGenBio AS ("BerGenBio" or the "Company"), ... appointed Hilde Furberg and Dr Stener ... Directors, effective immediately. Hilde Furberg ... biotech and is currently Senior Vice President Rare Diseases ... was Vice President and General Manager of Nordic Benelux ...
Breaking Medicine Technology:CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5BerGenBio Appoints Non-Executive Directors 2
... Oct. 24, 2011 PhotoMedex , Inc. (NASDAQ: ... including the XTRAC® excimer laser ( www.XTRACLaser.com ), is offering ... XTRAC psoriasis treatments for children, an underserved population of ... presented in recognition of World Psoriasis Day ...
... 24, 2011 HealthWarehouse.com, Inc. (OTC: HEWA), a ... it will begin providing prescription medications for WhiteGlove ... "We,re excited to have a national partner ... areas," said Robert Fabbio, co-founder and chief executive ...
Cached Medicine Technology:PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 2PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 3PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 4WhiteGlove Health Selects HealthWarehouse.com to Provide Prescription Medications to its Members Nationwide 2
(Date:9/1/2015)... Meadows, Ill. (PRWEB) , ... September 01, 2015 ... ... procedures done by members of the American Society for Dermatologic Surgery, according to ... , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures – which reflects ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia entrepreneur Marcella Ellis, ... strongly maintaining her firm’s success in the hair care and distribution industry through ... tour, Ellis will be providing “Look and learn” live demonstrations, as well as ...
(Date:9/1/2015)... , ... September 01, 2015 , ... The Jerry Segal ... The ACE Club and Green Valley Country Club in Lafayette Hill, PA. Over the ... more than $13.5 million for programs and services designed to support patients and their ...
(Date:9/1/2015)... ... September 01, 2015 , ... e-Spirit ... version 5.2 of the FirstSpirit Content Management System with new capabilities and enhancements ... version of FirstSpirit, companies will be well on their way to achieving digital ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... The ... and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection ... same mission – to raise awareness of the FSH Society and further FSHD research. ...
Breaking Medicine News(10 mins):Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3
... May 25, 2011 The American Society for Radiation Oncology ... Bernard Cummings, MB, ChB, FASTRO, as the Society,s 2011 Gold ... this honor at the Awards Ceremony held during ASTRO,s 53rd ... Fla. The Gold Medal is the Society,s highest honor. It ...
... by Trinity College Dublin that aims to ... selected for grant funding of 6 million by the ... NILVAD*, comprising 18 European universities, hospitals and pharmaceutical companies, ... treatment of Alzheimer,s disease (AD). Trinity College ...
... 20, most people have reached skeletal maturity and do not grow ... in the body also stopped by age 20. But a ... Chapel Hill has found evidence that, even though you,re not getting ... advance in age from 20 years to 79 years. "I ...
... National Institute of Standards and Technology (NIST) has released ... manufacturers evaluate the composition of their products and assure ... the human health effects of this popular beverage and ... prepared as part of an ongoing collaboration with the ...
... , TUESDAY, May 24 (HealthDay News) -- Long known as ... heart failure, a new study suggests. Research tracking more ... found that those whose diets included more baked and broiled ... -- had a 30 percent lower risk of heart failure ...
... care doctors have long been on the front lines of ... in 10 office visits and primary care doctors prescribe more ... University of Michigan Health System have developed a new tool ... which a patient,s depression has improved. The issue, the ...
Cached Medicine News:Health News:Ang, Cummings to receive ASTRO Gold Medal 2Health News:Clinical trials for new Alzheimer's disease treatment to be awarded European Commission €6m funding 2Health News:Pelvic widening continues throughout a person's lifetime, UNC study 2Health News:Care for a spot of (green) tea? New NIST reference materials for popular diet supplement 2Health News:Cooked Right, Fish Can Help a Woman's Heart 2Health News:Cooked Right, Fish Can Help a Woman's Heart 3Health News:New tool aims to improve measurement of primary care depression outcomes 2
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
Medicine Products: